Anaptysbio (ANAB) Net Equity Issued and Repurchased (2017 - 2026)

Anaptysbio (ANAB) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $14.0 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 4734.83% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (up 962.31% YoY) and the FY2025 annual result came in at $14.3 million, up 120.32% from the prior year.
• Net Equity Issued and Repurchased rose to $14.0 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $14.0 million in Q1 2026 to a low of $160000.0 in Q3 2023.
• A 5-year average of $2.8 million and a median of $922000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 94.07% — and 2026, when it surged 4734.83%.
• Tracing ANAB's Net Equity Issued and Repurchased over 5 years: stood at $3.4 million in 2022, then tumbled by 92.28% to $264000.0 in 2023, then surged by 110.23% to $555000.0 in 2024, then soared by 2100.36% to $12.2 million in 2025, then gained by 14.81% to $14.0 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $14.0 million (Q1 2026), $12.2 million (Q4 2025), and $336000.0 (Q3 2025), per Business Quant data.